Daily Clinical Briefing · Educational reading for healthcare professionals
Family observations and inherited patterns can reveal dementia while everyday abilities remain relatively preserved.
A 50% inheritance risk applies to children of a carrier in an autosomal dominant family, not to every case of frontotemporal dementia.
Sometimes it is the family, rather than the patient, who first recognises that something is changing. A person in middle age may still be driving, working and managing everyday activities, yet behaving in ways that relatives find increasingly unfamiliar. The initial explanations may involve depression, alcohol use or difficulties within a relationship.
Frontotemporal dementia deserves consideration when those changes are progressive.
Disease affecting the frontal and temporal lobes can disturb executive function and behaviour before memory loss becomes prominent. That creates a diagnostic problem because the patient may retain abilities that clinicians and families associate with being cognitively well.
The history therefore needs to go beyond memory. Ask relatives what has changed in everyday behaviour and whether similar patterns have appeared elsewhere in the family.
Family history can provide an important clue, but it also needs careful interpretation. Frontotemporal dementia includes several different disease processes, and not every case is inherited. Some familial forms involve MAPT mutations affecting tau, others involve C9-ORF72, which also has a genetic association with amyotrophic lateral sclerosis, or abnormalities involving progranulin.
In an affected family with an autosomal dominant mutation, each child of a carrier has a 50% chance of inheriting that mutation. That figure should not be applied indiscriminately to everyone diagnosed with frontotemporal dementia.
The distinction becomes particularly important when families consider genetic testing.
Someone may be determined to establish why a parent or sibling developed dementia without wanting to know whether they carry the same mutation. Predictive testing introduces questions about children, relationships and future plans. Different family members may reach very different decisions about whether and when they want that information.
MRI may demonstrate frontal or temporal atrophy, while genetic testing can help identify a relevant mutation. Neither removes the need for careful conversations about the consequences of a diagnosis.
There is also the prolonged experience of caregiving. Some families provide care over decades, gradually adjusting to changes in the person they know. A relative who appears composed and manages the practical demands of care may still be grieving those changes. Emotional control should not be mistaken for an absence of distress.
Treatment research brings another area where expectations need careful management. Reported reductions in tau in Alzheimer's disease provide a rationale for investigating MAPT-related frontotemporal dementia, but they do not establish clinical benefit in this different condition.
When a middle-aged patient develops progressive changes in personality or behaviour, a careful account from relatives and a detailed family history may redirect the diagnosis. Once inherited disease becomes a possibility, the next clinical conversation must also establish what each family member actually wants to know.
The RATE trial finds alternative anticoagulation strategies during ECMO non-inferior to standard-dose heparin for a composite outcome, without establishing superiority. CESAR evaluates referral to specialist ECMO-centre care rather than the effect of ECMO alone.
Hereditary fructose intolerance can remain undiagnosed into adulthood when patients instinctively avoid sweet foods. Fructose and sorbitol restriction remain central, while early ketohexokinase-inhibitor research offers preliminary insights into treatment and fatty liver mechanisms.
Child neurology training must accommodate neurogenetics, emerging therapies and learning through patient experience. Educators agree on several educational priorities, but the duration of paediatric training and the amount of adult neurology exposure remain unresolved.
Nutrition during cancer treatment should protect weight and muscle while accommodating gastrointestinal symptoms and individual preferences. Restrictive diets can worsen nutritional risk, and persistent bowel symptoms after treatment may have identifiable, treatable causes.
Frontotemporal dementia may begin with progressive personality and behavioural changes rather than memory loss. Familial disease introduces difficult decisions about genetic testing, inherited risk and future planning, while prolonged caregiving creates significant emotional and practical demands.
When assessing progressive behavioural changes in a middle-aged patient, ask relatives for specific examples and whether similar patterns have occurred elsewhere in the family. Distinguish establishing a family diagnosis from an individual's decision about predictive genetic testing. Ask carers about their practical responsibilities and the emotional impact of providing care over time.
A middle-aged adult continues working and driving, but relatives report progressively unusual behaviour and marked personality changes. A family member experienced similar difficulties several years earlier. Which neurological diagnosis should be considered despite the absence of prominent memory loss?
Frontotemporal dementia. Behavioural and personality changes may precede significant memory impairment, and a similar pattern in relatives raises the possibility of inherited disease.
An adult reports lifelong avoidance of sweet foods because eating them causes immediate nausea. The patient has never undergone metabolic investigation, and the dietary restriction has largely prevented symptoms. Which inherited metabolic disorder should be considered?
Hereditary fructose intolerance, caused by aldolase B deficiency. Self-selected fructose avoidance can conceal the disorder into adulthood. Sorbitol also requires restriction because it is a precursor of fructose.
A patient receiving chemotherapy loses weight and muscle and proposes fasting and removing all dietary sugar to prevent further cancer growth. What important nutritional concern should influence the advice given?
Restricting energy intake cannot selectively starve the cancer and may worsen weight and muscle loss, weakness and treatment tolerance. Nutritional advice should prioritise adequate intake and individual dietary support rather than unsupported restrictive diets.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)